Business
BioLineRx to Report 2024 Annual Results on March 31, 2025
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release its audited financial results for the year ended December 31, 2024 on Monday, March 31, 2025, before the U.S. markets open.
About this update from Biolinerx Ltd.
[{"type":"text","content":"Management to Hold Conference Call at 8:30 a.m. EDT","length":51,"tagName":"p","attribs":{}},{"type":"text","content":"TEL AVIV, Israel, March 24, 2025 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release its audited financial results for the year ended December 31, 2024 on Monday, March 31, 2025, before the U.S. markets open.","length":360,"tagName":"p"},{"type":"text","content":" ","length":6,"tagName":"p"},{"type":"image","alt":"BioLineRx_Ltd_Logo","displaySize":"","headline":null,"caption":"BioLineRx_Ltd_Logo","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":107,"url":"https://media.zenfs.com/en/prnewswire.com/b069ac9f15d655849a2707e7c3811a1a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/OyiE7Swe7H0ATLTDAG4i.g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE4OTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/b069ac9f15d655849a2707e7c3811a1a","width":400,"height":107}}},{"type":"text","content":"The Company will host a conference call at 8:30 a.m. EDT featuring remarks by Philip Serlin, Chief Executive Officer.","length":117,"tagName":"p"},{"type":"text","content":"To access the conference call, please dial +1-888-281-1167 from the U.S. or +972-3-918-0685 internationally. A live webcast and a replay of the call can be accessed through the event page on the Company's website. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast. A replay of the call will be available approximately two hours after completion of the live conference call. A dial-in replay of the call will be available until April 2, 2025; please dial +1-888-295-2634 from the US or +972-3-925-5904 internationally.","length":604,"tagName":"p"},{"type":"text","content":"About BioLineRx","length":15,"tagName":"p"},{"type":"text","content":"BioLineRx Ltd. (NASDAQ/TASE: BLRX) is a biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases. The company's first approved product is APHEXDA® (motixafortide) with an indication in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma, which is being developed and commercialized ...